Compare BIO-TECHNE Corp (TECH) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United Parcel Service Inc — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.33B), while United Parcel Service Inc trades at $99.46 (market cap $84.41B). The key difference: United Parcel Service Inc is far larger — about 7.5× BIO-TECHNE Corp's market cap, and United Parcel Service Inc pays the higher dividend (6.61%). Which is the better fit depends on your goals.
| TECH | UPS | |
|---|---|---|
Market Cap | $11.33B | $84.41B |
Sector | Health | Industrials |
52-Week High | $72.48 | $120.00 |
52-Week Low | $43.31 | $82.58 |
Enterprise Value | $11.35B | $108.43B |
Dividend Yield | 0.44% | 6.61% |
Volume | — | 2,288,643 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with neutral technical signals and mixed earnings performance. The company reported Q4 2026 revenue of $321.2 million, beating estimates, but net income margins have declined from 25.09% in 2023 to 14.96% in 2026. Key developments include a pending acquisition by Merck KGaA at $73.00 per share and a quarterly dividend of $0.08. Analyst consensus is split with 46% buy and 54% hold ratings.
The stock offers moderate upside to the acquisition price, supported by solid cash flow and institutional interest, but faces risks from margin compression and ongoing shareholder investigations. Valuation multiples like P/E of 62.28 suggest premium pricing, requiring careful assessment of growth sustainability amid competitive and integration challenges.
UPS stock trades at $100.48, down 1.78% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. The company announced a $2B+ global investment to enhance logistics and appointed a new Chief Global Operations Officer, signaling strategic shifts. Valuation metrics include a P/E of 18.68 and P/S of 0.95, with a dividend yield of 6.2% based on the $1.64 per share payout.
The outlook is mixed: analyst consensus leans neutral with a $117.90 price target, but risks include declining net income margins and high dividend payout ratios limiting investment flexibility. Upside potential exists from efficiency gains and global expansion, while macroeconomic pressures and competitive threats pose challenges for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
